Skip to main content

Table 7 Trends in post-bronchodilator (PostBD) spirometric parameters during follow up

From: Longitudinal trends in clinical characteristics and lung function of patients with severe asthma under treatment in Brazil

Study visits

V0

V1

V8

p valuea

p valuea

p valueb

(139)

(139)

(139)

V0xV1

V1x V8

V0xV1xV8

FVC L

2.7 (2.3–3.5)

2.8 (2.3–3.4)

2.6 (2.1–3.1)

0.98

<0.01

0.00

FVC (% pred)

91.0 (77.0–101.0)

91.0(79.0–102.0)

82.2 (73.6–92.0)

0.43

<0.01

0.00

FEV1 (L)

1.9 (1.4–2.3)

1.9 (1.5–2.4)

1.7 (1.3–2.2)

0.41

<0.01

0.00

FEV1 (%pred)

73.0 (60.0–85.0)

73.0 (63.0–86.0)

67.2 (56.3–80.3)

0.15

<0.01

0.00

FEV1/FVC

0.7 (0.6–0.8)

0.7 (0.6–0.8)

0.7 (0.6–0.7)

0.34

0.21

0.47

FEV1/FVC (%pred)

82.0 (68.0–93.0)

83.0 (71.0–92.0)

81.5 (74.7–91.4)

0.23

0.41

0.18

FEF25–75% (L/s)

1.0 (0.6–1.6)

1.1 (0.6–1.8)

1.0 (0.7–1.6)

0.04

<0.01

0.05

FEF25–75% (%pred)

34.0 (22.0–57.0)

41.0 (25.0–64.0)

37.8 (29.9–62.7)

0.04

0.88

0.05

BD chg (ml)

290.0(180.0–440.0)

160.0(40.0–340.0)

170.0(70.0–300.0)

<0.01

0.87

0.00

BD chg (%)

18.0 (11.0–28.0)

10.0 (2.0–22.0)

11.6 (5.0–20.7)

<0.01

0.10

0.00

  1. Note: aWilcoxon and bFriedman tests; FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, FEF forced expiratory flow, BD bronchodilator; data presented as median and interquartile range